{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:54:04Z","timestamp":1791849244437,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangzhou Science and Technology Projects","award":["2024A04J4722"],"award-info":[{"award-number":["2024A04J4722"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010149"],"award-info":[{"award-number":["2023A1515010149"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Existing studies have focused on secondary hyperparathyroidism with elevated PTH in CKD, but survival outcomes of CKD patients with low PTH remain underexplored. This study examines prognostic implications of PTH reduction from different etiologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective cohort study included CKD stages 4\u20135 patients with PTH\u2009&lt;\u2009150 pg\/mL from the China Renal Data System, categorized into parathyroidectomy (PTX), Drug, and Unknown Causes (UC) groups based on low PTH etiology. Mortality was analyzed using Kaplan-Meier curves and Cox regression. Covariates were selected by univariate or LASSO regression. Inverse probability weighting was applied in sensitivity analyses to reduce confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 17 175 patients were included: 423 in the PTX group, 10 519 in the Drug group, and 6 233 in the UC group. PTX group had the highest survival rate (79.44%) and lowest cardiovascular mortality (1.61%), followed by Drug group (69.21% and 4.60%) and UC group (50.76% and 9.83%) (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Both Drug group and UC group were consistently associated with significantly higher mortality risk compared with the PTX group (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). After applying IPW to balance key covariates, PTX group remained associated with the lowest mortality risk (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). However, in some sensitivity analyses, no significant difference was observed between PTX group and Drug group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pharmacological therapy and PTX were associated with more favorable survival profiles than low PTH of unknown causes in patients with advanced CKD, though residual confounding due to baseline differences between groups cannot be fully excluded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05202-7","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:33:39Z","timestamp":1784205219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis comparison in chronic kidney disease stages 4\u20135 patients with low parathyroid hormone level due to different causes"],"prefix":"10.1186","volume":"27","author":[{"given":"Xiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"4","key":"5202_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/jcsm.12722","volume":"12","author":"H Komaba","year":"2021","unstructured":"Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, et al. Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. J Cachexia Sarcopenia Muscle. 2021;12(4):855\u201365.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"18","key":"5202_CR2","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/jama.2024.16338","volume":"332","author":"JE Flythe","year":"2024","unstructured":"Flythe JE, Watnick S. Dialysis for Chronic Kidney Failure: A Review. JAMA. 2024;332(18):1559\u201373.","journal-title":"JAMA"},{"issue":"3","key":"5202_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","volume":"107","author":"M Ketteler","year":"2025","unstructured":"Ketteler M, Evenepoel P, Holden RM, Isakova T, Jorgensen HS, Komaba H, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;107(3):405\u201323.","journal-title":"Kidney Int"},{"issue":"5","key":"5202_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40620-021-01082-2","volume":"34","author":"M Ketteler","year":"2021","unstructured":"Ketteler M, Ambuhl P. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. J Nephrol. 2021;34(5):1405\u201318.","journal-title":"J Nephrol"},{"issue":"4","key":"5202_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","volume":"78","author":"M Pazianas","year":"2021","unstructured":"Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021;78(4):582\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"5202_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5551\/jat.RV22006","volume":"30","author":"S Yamada","year":"2023","unstructured":"Yamada S, Nakano T. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. J Atheroscler Thromb. 2023;30(8):835\u201350.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"5202_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T. Evocalcet study g. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818\u201325.","journal-title":"Kidney Int"},{"issue":"3","key":"5202_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/ASN.2020050598","volume":"32","author":"Y Isaka","year":"2021","unstructured":"Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F, Sakaguchi Y, et al. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. J Am Soc Nephrol. 2021;32(3):723\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"5202_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s40620-020-00962-3","volume":"34","author":"VM Saglimbene","year":"2021","unstructured":"Saglimbene VM, Su G, Wong G, Natale P, Ruospo M, Palmer SC, et al. Dietary intake in adults on hemodialysis compared with guideline recommendations. J Nephrol. 2021;34(6):1999\u20132007.","journal-title":"J Nephrol"},{"issue":"1","key":"5202_CR10","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1038\/s41467-023-39474-6","volume":"14","author":"C Wu","year":"2023","unstructured":"Wu C, Zhang Y, Nie S, Hong D, Zhu J, Chen Z, et al. Predicting in-hospital outcomes of patients with acute kidney injury. Nat Commun. 2023;14(1):3739.","journal-title":"Nat Commun"},{"issue":"7","key":"5202_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1681\/ASN.0000000000000125","volume":"34","author":"X Xu","year":"2023","unstructured":"Xu X, Nie S, Xu H, Liu B, Weng J, Chen C, et al. Detecting Neonatal AKI by Serum Cystatin C. J Am Soc Nephrol. 2023;34(7):1253\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"5202_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.7326\/M24-0178","volume":"177","author":"S Zhou","year":"2024","unstructured":"Zhou S, Chen R, Liu J, Guo Z, Su L, Li Y, et al. Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin: A Multi-database Cohort Study. Ann Intern Med. 2024;177(12):1641\u201351.","journal-title":"Ann Intern Med"},{"issue":"4 Suppl 3","key":"5202_CR13","first-page":"S1","volume":"42","author":"F National Kidney","year":"2003","unstructured":"National Kidney F. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1\u2013201.","journal-title":"Am J Kidney Dis"},{"key":"5202_CR14","doi-asserted-by":"crossref","unstructured":"Bellorin-Font E, Rojas E, Martin KJ. Bone disease in chronic kidney disease and kidney transplant. Nutrients. 2022;15(1).","DOI":"10.3390\/nu15010167"},{"issue":"6","key":"5202_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1053\/ajkd.2001.29254","volume":"38","author":"MM Avram","year":"2001","unstructured":"Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001;38(6):1351\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"5202_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2015.12.001","volume":"89","author":"E Merle","year":"2016","unstructured":"Merle E, Roth H, London GM, Jean G, Hannedouche T, Bouchet JL, et al. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney Int. 2016;89(3):666\u201374.","journal-title":"Kidney Int"},{"issue":"3","key":"5202_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","volume":"15","author":"LA Stevens","year":"2004","unstructured":"Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15(3):770\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"5202_CR18","doi-asserted-by":"crossref","unstructured":"Sircuta AF, Grosu ID, Schiller A, Petrica L, Ivan V, Schiller O, et al. Associations between inflammatory and bone turnover markers and mortality in hemodialysis patients. Biomedicines. 2025;13(5).","DOI":"10.3390\/biomedicines13051163"},{"issue":"6","key":"5202_CR19","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl. 2011;26(6):1948\u201355.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"5202_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2215\/CJN.10390917","volume":"13","author":"WL Lau","year":"2018","unstructured":"Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952\u201361.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"5202_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98\u2013109.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5202_CR22","unstructured":"Drueke TB, et al. Hyperparathyroidism in Chronic Kidney Disease. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, editors. Endotext. South Dartmouth (MA); 2000."},{"issue":"26","key":"5202_CR23","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"ET Investigators","year":"2012","unstructured":"Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"10","key":"5202_CR24","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1016\/j.ekir.2024.07.008","volume":"9","author":"H Komaba","year":"2024","unstructured":"Komaba H, Imaizumi T, Hamano T, Fujii N, Abe M, Hanafusa N, et al. Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis. Kidney Int Rep. 2024;9(10):2956\u201369.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"5202_CR25","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1210\/clinem\/dgac142","volume":"107","author":"H Komaba","year":"2022","unstructured":"Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, et al. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022;107(7):2016\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5202_CR26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/ndt\/gfad213","volume":"39","author":"S Goto","year":"2024","unstructured":"Goto S, Hamano T, Fujii H, Taniguchi M, Abe M, Nitta K, et al. Hypocalcemia and cardiovascular mortality in cinacalcet users. Nephrol Dial Transpl. 2024;39(4):637\u201347.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"5202_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ekir.2024.01.002","volume":"9","author":"S Yamamoto","year":"2024","unstructured":"Yamamoto S, Jorgensen HS, Zhao J, Karaboyas A, Komaba H, Vervloet M, et al. Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS. Kidney Int Rep. 2024;9(4):863\u201376.","journal-title":"Kidney Int Rep"},{"issue":"10","key":"5202_CR28","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2215\/CJN.0000000000000253","volume":"18","author":"T Shigematsu","year":"2023","unstructured":"Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, et al. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. Clin J Am Soc Nephrol. 2023;18(10):1300\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"5202_CR29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1159\/000504139","volume":"44","author":"Y Zu","year":"2019","unstructured":"Zu Y, Lu X, Song J, Yu L, Li H, Wang S. Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis. Kidney Blood Press Res. 2019;44(6):1327\u201338.","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"5202_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2023.04.003","volume":"82","author":"WG Yeung","year":"2023","unstructured":"Yeung WG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, et al. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2023;82(5):543\u201358.","journal-title":"Am J Kidney Dis"},{"key":"5202_CR31","doi-asserted-by":"publisher","first-page":"1169793","DOI":"10.3389\/fendo.2023.1169793","volume":"14","author":"T Hiramitsu","year":"2023","unstructured":"Hiramitsu T, Hasegawa Y, Futamura K, Okada M, Goto N, Narumi S, et al. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Front Endocrinol (Lausanne). 2023;14:1169793.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"5202_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.ajkd.2023.10.007","volume":"83","author":"AY Wang","year":"2024","unstructured":"Wang AY, Tang TK, Yau YY, Lo WK. Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial. Am J Kidney Dis. 2024;83(4):456\u201366. e1.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"5202_CR33","doi-asserted-by":"publisher","first-page":"c113","DOI":"10.1159\/000326683","volume":"119","author":"J Fotheringham","year":"2011","unstructured":"Fotheringham J, Balasubramanian SP, Harrison B, Wilkie M. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival - a single-centre study in a stage 5 chronic kidney disease population. Nephron Clin Pract. 2011;119(2):c113\u201320.","journal-title":"Nephron Clin Pract"},{"issue":"10","key":"5202_CR34","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1507\/endocrj.EJ19-0036","volume":"66","author":"WW Kim","year":"2019","unstructured":"Kim WW, Rhee Y, Kim BS, Kim K, Lee CR, Kang SW, et al. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism. Endocr J. 2019;66(10):881\u20139.","journal-title":"Endocr J"},{"key":"5202_CR35","doi-asserted-by":"publisher","first-page":"6934706","DOI":"10.1155\/2017\/6934706","volume":"2017","author":"QP Xi","year":"2017","unstructured":"Xi QP, Xie XS, Zhang L, Zhang R, Xiao YF, Jin CG, et al. Impact of Different Levels of iPTH on All-Cause Mortality in Dialysis Patients with Secondary Hyperparathyroidism after Parathyroidectomy. Biomed Res Int. 2017;2017:6934706.","journal-title":"Biomed Res Int"},{"issue":"4","key":"5202_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.jrn.2009.10.006","volume":"20","author":"R Dukkipati","year":"2010","unstructured":"Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010;20(4):243\u201354.","journal-title":"J Ren Nutr"},{"issue":"1","key":"5202_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.jrn.2010.10.006","volume":"21","author":"U Feroze","year":"2011","unstructured":"Feroze U, Molnar MZ, Dukkipati R, Kovesdy CP, Kalantar-Zadeh K. Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients. J Ren Nutr. 2011;21(1):100\u20134.","journal-title":"J Ren Nutr"},{"issue":"4","key":"5202_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2215\/CJN.01730218","volume":"13","author":"B Hocher","year":"2018","unstructured":"Hocher B, Zeng S. Clear the Fog around Parathyroid Hormone Assays: What Do iPTH Assays Really Measure? Clin J Am Soc Nephrol. 2018;13(4):524\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"5202_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000357969","volume":"37","author":"JR Lu","year":"2014","unstructured":"Lu JR, Yi Y, Tian J, Xiong CX, Wang XH, Hu J, et al. Prevalence and determinants of parathyroid dysfunction in elderly patients on hemodialysis. Blood Purif. 2014;37(2):119\u201324.","journal-title":"Blood Purif"},{"issue":"4","key":"5202_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1053\/ajkd.2002.35693","volume":"40","author":"V Panuccio","year":"2002","unstructured":"Panuccio V, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Asahi K, et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis. 2002;40(4):810\u20135.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05202-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:22:28Z","timestamp":1791847348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05202-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5202"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05202-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CRDS has received approval from the China Office of Human Genetic Resources for Data Preservation Application under the Ministry of Science and Technology of China (approval number: 2021- BC0037), which waives the requirement for patient informed consent due to the retrospective nature of the study. The study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"606"}}